Diagnostic Value of Combined Detection of Anti-cyclic Citrullinated Peptide Antibody and Rheumatoid Factor in Rheumatoid Arthritis
Objective To evaluate the value of combined detection of anti-cyclic citrullinated peptide antibody and rheumatoid factor in the diagnosis of rheumatoid arthritis. Methods Ninety patients with rheumatoid arthritis with similar condition were selected from our hospital for a series of clinical trials. The patients were treated from May 2016 to November 2018. The 90 patients with rheumatoid arthritis were divided into two groups, 45 patients in each group. One group of patients with rheumatoid arthritis was detected by rheumatoid factor test, the other group was detected by anticyclic citrullinated peptide antibody combined with rheumatoid factor test, and then the results of the two groups of patients with rheumatoid arthritis were compared. Results 42 patients in the experimental group were positive, the positive detection rate was 93.3％; 32 patients in the control group were positive, the positive detection rate was 83.6％; the positive detection rate of the experimental group was significantly higher than that of the control group, the different was statistically significant (P<0.05), with statistical significance. Conclusion The positive detection rate of anti-cyclic citrullinated peptide antibody combined with rheumatoid factor in the diagnosis of rheumatoid arthritis is high, which has high diagnostic value and deserves further promotion.
NETL
NSTL
万方数据
维普
